諾誠健華(688428.SH):創新藥ICP-332在中重度特應性皮炎成年患者中取得了積極的臨牀試驗結果
格隆匯12月17日丨諾誠健華(688428.SH)公佈,公司於近日獲悉,公司創新藥ICP-332在中重度特應性皮炎成年患者中進行的Ⅱ期隨機、雙盲、安慰劑對照研究中取得了積極的臨牀試驗結果。ICP-332是公司自主研發的具有全球知識產權的1類創新藥,屬於新型口服TYK2抑制劑。TYK2是一種非受體酪氨酸激酶,屬於Janus激酶(JAK)家族,是JAK-STAT信號通道上一個重要激酶,在T細胞炎症發病機制上起到重要作用。作為高選擇性的新型TYK2抑制劑,ICP-332對TYK2具有強效抑制活性,對JAK2的選擇性高達約400倍,可避免或降低因JAK2抑制所致的不良反應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.